Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer (Q43591690)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 October 2013

Language	Label	Description	Also known as
English	Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer	scientific article published on 8 October 2013

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer (English)

1 reference

Europe PubMed Central

25 November 2017

estrogen-receptor positive breast cancer

0 references

7

object named as

Hiroyuki Takei

1 reference

Europe PubMed Central

25 November 2017

Hironobu Sasano

14

object named as

Hironobu Sasano

1 reference

Europe PubMed Central

25 November 2017

9

object named as

Shinji Ohno

1 reference

Europe PubMed Central

25 November 2017

Norikazu Masuda

2

object named as

Norikazu Masuda

1 reference

Europe PubMed Central

25 November 2017

13

object named as

Hiroji Iwata

1 reference

Europe PubMed Central

25 November 2017

15

object named as

Masakazu Toi

1 reference

Europe PubMed Central

25 November 2017

4

object named as

Shigehira Saji

1 reference

Europe PubMed Central

25 November 2017

Katsumasa Kuroi

5

object named as

Katsumasa Kuroi

1 reference

Europe PubMed Central

25 November 2017

author name string

Takayuki Ueno

1

1 reference

Europe PubMed Central

25 November 2017

Takeharu Yamanaka

3

1 reference

Europe PubMed Central

25 November 2017

Nobuaki Sato

6

1 reference

Europe PubMed Central

25 November 2017

Yutaka Yamamoto

8

1 reference

Europe PubMed Central

25 November 2017

Hiroko Yamashita

10

1 reference

Europe PubMed Central

25 November 2017

Kazufumi Hisamatsu

11

1 reference

Europe PubMed Central

25 November 2017

Kenjiro Aogi

12

1 reference

Europe PubMed Central

25 November 2017

publication date

8 October 2013

1 reference

Europe PubMed Central

25 November 2017

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

25 November 2017

19

1 reference

Europe PubMed Central

25 November 2017

4

1 reference

Europe PubMed Central

25 November 2017

607-613

1 reference

Europe PubMed Central

25 November 2017

https://scigraph.springernature.com/pub.10.1007/s10147-013-0614-x

0 references

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Letrozole in the neoadjuvant setting: the P024 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0614-X

21 January 2018

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Locally Advanced and Inflammatory Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24101215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-013-0614-X

1 reference

Europe PubMed Central

25 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43591690&oldid=2101742139"